CA56 - Hidradénome nodulaire malin : une nouvelle observation

Moutaoui, L. El; Disky, A.; Zouhair, K.; Azouzi, S.; Belhama, S.; Benchikhi, H.

doi:10.1016/s0151-9638(07)89154-x

Cited by 6 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy as an adjuvant modality of treatment has been established in the 1990s for head and neck malignant hidradenoma with positive margins. Adjuvant modalities of treatment acquire more importance as the tumour has a 10-50% chance of recurrence despite aggressive surgical treatment [ 17 ]. Histopathological factors that herald the necessity of adjuvant radiotherapy include anaplastic tissue architecture, lympho-neurovascular invasion, positive margins, extracapsular lymphatic extension, and nodal sterilization [ 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

Malignant Nodular Hidradenoma of the Left Knee: A Malignant Mystery With an Overview of Literature

Gokulanathan¹,

Pandjatcharam²,

Kalaranjani³

et al. 2022

Cureus

View full text Add to dashboard Cite

Malignant nodular hidradenoma is a rare eccrine sweat gland neoplasm characterized by recurrence, metastasis, and a locally aggressive course. In our case report, a 74-year-old man presented with a seemingly benign swelling which was persistent for the last 30 years, which was excised at an outside institute. Since the patient presented to the hospital during the peak of the pandemic, considering the age of the patient, the pandemic situation, the logistics of radiotherapy during such a situation, preserving the knee joint function in view of close proximity of the tumour to the joint, it was decided to keep the patient on follow up and continue expectant management. After a follow-up period of 24 months, no locoregional recurrence or metastasis has been observed. The patient is on annual follow-up with clinical examination and PET-CECT imaging.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant Nodular Hidradenoma of the Left Knee: A Malignant Mystery With an Overview of Literature

Gokulanathan¹,

Pandjatcharam²,

Kalaranjani³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…The prognosis of hidradenoma is often good but malignant transformation into hidradenosarcoma is possible, this risk is increased after the age of 50 years. The malignant form described by KEASBEY and HADLEY in 1954 [9] has an important local aggressiveness, with lymph node and bone metastases but can also be cutaneous, hepatic and pulmonary metastases to [10]. This malignant form often develops from a benign lesion but a de novo malignant hidradenoma is possible.…”

Section: Discussionmentioning

confidence: 99%

Giant Hidradenoma of Limbs: A Report of Two Pediatric Cases

Jlalia¹,

Bahroun²,

Kamoun³

et al. 2017

J Orthop Oncol

View full text Add to dashboard Cite

Hidradenoma is a rare benign tumor that develops of the eccrine sweat glands. We report here two cases of benign giant hidradenoma with a clear cell variant in one case and nodular in the other. The tumor was localized on the forearm in a patient aged 6 years and in the foot in a 14-year-old child. An excisional biopsy was performed in both patients. Evolution was marked by a good outcome without recurrence. We try through this paper to review an uncommon tumor which his eccrine origin is controversial and which biological behavior was badly known.

show abstract

“…Surgery is the mainstay of the treatment and postsurgical survival rate at five years is found to be less than 30% [ 11 ]. The postsurgical recurrence rate is 50% [ 12 ]. So, for improving local control, external beam radiotherapy may be given as an adjuvant treatment, but it is controversial [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Current management approach to hidradenocarcinoma: a comprehensive review of the literature

Soni

Bansal

Kaushal

et al. 2015

ecancer

109

View full text Add to dashboard Cite

Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials.

show abstract

CA56 - Hidradénome nodulaire malin : une nouvelle observation

Cited by 6 publications

References 2 publications

Malignant Nodular Hidradenoma of the Left Knee: A Malignant Mystery With an Overview of Literature

Malignant Nodular Hidradenoma of the Left Knee: A Malignant Mystery With an Overview of Literature

Giant Hidradenoma of Limbs: A Report of Two Pediatric Cases

Current management approach to hidradenocarcinoma: a comprehensive review of the literature

Contact Info

Product

Resources

About